Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20925993 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
Condition: Crohn's Disease
Interventions: Biological: Certolizumab pegol;   Other: Placebo

Indicates status has not been verified in more than two years